Deals

Bain, Cinven Weighs Sale of €10 Billion Drugmaker Stada

  • Private equity owners asking banks to pitch for roles on deal
  • Owners may also consider an IPO of German group: sources
Photographer: Alex Kraus/Bloomberg
Lock
This article is for subscribers only.

The private equity owners of Stada Arzneimittel AG are weighing options for the German drugmaker, including a possible sale, people with knowledge of the matter said.

Bain Capital and Cinven are in the early stages of asking banks to pitch for roles on a possible transaction, the people said, asking not to be identified discussing confidential information. A sale could value Stada at €10 billion ($10.1 billion) or more, the people said.